Sulfadiazine
chemical compound
Sulfadiazine is an antibiotic. Used together with pyrimethamine, a dihydrofolate reductase inhibitor, it is the treatment of choice for toxoplasmosis, which is caused by a protozoan parasite. It is a second-line treatment for otitis media, prophylaxis of rheumatic fever, chancroid, chlamydia, and infections by Haemophilus influenzae. It is also used as adjunct therapy for chloroquine-resistant malaria and several forms of bacterial meningitis. It is taken by mouth. Sulfadiazine is available in multiple generic tablets of 500 mg. For urinary tract infections, the usual dose is 4 to 6 grams daily in 3 to 6 divided doses.
Common side effects include nausea, diarrhea, headache, fever, rash, depression, and pancreatitis. It should not be used in people who have severe liver problems, kidney problems, or porphyria. If used during pregnancy, it may increase the risk of kernicterus in the baby.
“Sulfadiazine” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Sulfadiazine, chemical and compound can confirm, complicate or overturn.
Why this record matters
“Sulfadiazine” is worth following because a concise public description often conceals a longer documentary argument. Here, Sulfadiazine, chemical and compound provides the most credible route into that argument.
The date and method of observation matter as much as the stated conclusion, especially where classification or consensus has changed. The source revision retrieved here is dated Feb 9, 2026. The linked authority identifier is Q2555060. None of the 0 selected statements returned an explicit reference.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Sulfadiazine”, its source revision and the description used here.
- Expand the search: follow Sulfadiazine primary sources, Sulfadiazine archive and Sulfadiazine research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Sulfadiazine”?
- Has classification or technical consensus changed since the cited source?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “Sulfadiazine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.